MRTX1133
- Product Name
- MRTX1133
- CAS No.
- 2621928-55-8
- Chemical Name
- MRTX1133
- Synonyms
- MRTX1133;KRAS,Ras,MRTX 1133,G12D,cells,active,wild-type,phosphorylation,mutant,MRTX1133,inactive,ERK,inhibit,tumor,states,MRTX-1133,Inhibitor;4-(4-(3,8-Diazabicyclo[3.2.1]octan-3-yl)-8-fluoro-2-(((2R,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl)methoxy)pyrido[4,3-d]pyrimidin-7-yl)-5-ethynyl-6-fluoronaphthalen-2-ol;4-[4-[3,8-Diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(2S,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol;4-[4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoro-2-Naphthalenol;2-Naphthalenol, 4-[4-(3,8-diazabicyclo[3.2.1]oct-3-yl)-8-fluoro-2-[[(2R,7aS)-2-fluorotetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoro-;4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(2S,7aS)-2-fluorohexahydro-1H-pyrrolizin-7a-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol
- CBNumber
- CB89021600
- Molecular Formula
- C33H31F3N6O2
- Formula Weight
- 600.63
- MOL File
- 2621928-55-8.mol
MRTX1133 Property
- Density
- 1.49±0.1 g/cm3(Predicted)
- solubility
- DMSO:50.0(Max Conc. mg/mL);83.24(Max Conc. mM)
- form
- A solid
- pka
- 8.05±0.40(Predicted)
- color
- Yellow to brown
- InChIKey
- SCLLZBIBSFTLIN-IFMUVJFISA-N
- SMILES
- C1=C2C(C(C#C)=C(F)C=C2)=C(C2N=CC3=C(N4CC5NC(CC5)C4)N=C(OC[C@]45C[C@@H](F)CN4CCC5)N=C3C=2F)C=C1O
Hazard and Precautionary Statements (GHS)
- Symbol(GHS)
-
- Signal word
- Warning
- Hazard statements
-
H315Causes skin irritation
H319Causes serious eye irritation
- Precautionary statements
-
P264Wash hands thoroughly after handling.
P264Wash skin thouroughly after handling.
P280Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352IF ON SKIN: wash with plenty of soap and water.
P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.
P321Specific treatment (see … on this label).
P332+P313IF SKIN irritation occurs: Get medical advice/attention.
P337+P313IF eye irritation persists: Get medical advice/attention.
MRTX1133 Chemical Properties,Usage,Production
Uses
MRTX1133 is a potent and selective KRAS G12D inhibitor that targets KRAS G12D protein in both the active and inactive states. In preclinical studies, MRTX1133 exhibited a long half-life, was able to bind to KRAS G12D protein in both active and inactive states, and selectively inhibited KRAS G12D-mutated cancer cells. In G12D mutant tumor models, it showed dose-dependent selective inhibition of the KRAS pathway and tumor regression.
Description
MRTX1133 is a potent KRASG12D inhibitor. Treatment by intraperitoneal (IP) administration is effective against tumours in xenograft mice with KRASG12D mutations. However, MRTX1133 has low oral bioavailability (only 0.5%), which may be related to gastrointestinal malabsorption. In addition, MRTX1133 has two hydrogen bond donors (HBDs): a phenolic group and a secondary amine moiety. And the secondary amine molecule is considered to be the main cause of malabsorption. Currently, an oral prodrug of MRTX1133 has been developed to effectively treat tumours in xenograft mice with the KRASG12D mutation[1].
Chemical Properties
Solid powder.
Uses
MRTX1133 is primarily used in studies targeting advanced solid tumours with KRASG12D mutations, such as human pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and colorectal cancer.
Biological Functions
MRTX1133 is a noncovalent, potent, and selective KRAS G12D inhibitor. It optimally fills the switch II pocket and extends three substituents to favorably interact with the protein, resulting in an estimated KD against KRAS G12D of 0.2 pM. MRTX1133 prevents SOS1-catalyzed nucleotide exchange and/or formation of the KRAS G12D/GTP/RAF1 complex, thereby inhibiting mutant KRAS-dependent signal transduction. This inhibitor selectively inhibits KRAS G12D mutants but not KRAS wild-type tumor cells. MRTX1133 has single-digit nanomolar activity in cellular assays and marked in vivo efficacy in tumor models harboring KRAS G12D mutations.
target
KRas G12D
storage
Dry, dark and at 0-4℃ for short term (days to weeks) or -20℃ for long term (months to years).
References
[1] XIANG JI*, JIASHENG LU*; Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRASG12D Mutation[J]. ACS Omega, 2023. DOI:10.1021/acsomega.3c00329.
MRTX1133 Preparation Products And Raw materials
Raw materials
Preparation Products
MRTX1133 Suppliers
- Tel
- 18051384581
- sales@chemhifuture.com
- Country
- China
- ProdList
- 2995
- Advantage
- 58
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8012
- Advantage
- 62
- Tel
- 0519-85788828 13775037613
- sales@chemrenpharm.com
- Country
- China
- ProdList
- 3600
- Advantage
- 58
- Tel
- 13606124132;13656121842
- luyan0021@163.com
- Country
- China
- ProdList
- 219
- Advantage
- 58
- Tel
- 63313187 15358055255
- Fax
- QQ：63313187
- 63313187@qq.com
- Country
- China
- ProdList
- 1986
- Advantage
- 58
- Tel
- 15869524721
- 3525679403@qq.com
- Country
- China
- ProdList
- 4006
- Advantage
- 58
- Tel
- 13720134139 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 5816
- Advantage
- 58
- Tel
- 17721492509
- 643638326@qq.com
- Country
- China
- ProdList
- 5345
- Advantage
- 58
- Tel
- 15342225168
- yutianchun2007@126.com
- Country
- China
- ProdList
- 10003
- Advantage
- 58
- Tel
- 021-021-58432009 400-005-6266
- Fax
- 021-58436166
- sales8178@energy-chemical.com
- Country
- China
- ProdList
- 44688
- Advantage
- 61
View Lastest Price from MRTX1133 manufacturers
- Product
- MRTX1133 2621928-55-8
- Price
- US $0.00-0.00/MG
- Min. Order
- 1MG
- Purity
- 98
- Supply Ability
- 100G
- Release date
- 2024-04-17